GSK-3β Inhibitor, elraglusib (9-ING-41), pancreatic cancer, combination, previously untreated
Anti-vascular endothelial growth factor, receptor tyrosine kinase inhibitors, neuroendocrine tumors, toxicity, objective response rate, progression-free survival, systematic review & meta-analysis